Development of germinoma during the treatment of systemic-onset juvenile idiopathic arthritis with infliximab

被引：2
作者：
Takezaki, Shunichiro [1 ]
Okura, Yuka [1 ]
Ichikawa, Mizuho [1 ]
Suzuki, Daisuke [1 ]
Ohshima, Junjiro [1 ]
Kaneda, Makoto [1 ]
Cho, Yuko [1 ]
Yamada, Masafumi [1 ]
Kawamura, Nobuaki [1 ]
Iguchi, Akihiro [1 ]
Kobayashi, Ichiro [1 ]
Ariga, Tadashi [1 ]
机构：
[1] Hokkaido Univ, Sch Med, Dept Pediat, Kita Ku, Sapporo, Hokkaido 0608638, Japan
来源：
MODERN RHEUMATOLOGY | 2012年 / 22卷 / 04期
关键词：
Juvenile idiopathic arthritis; Infliximab; Malignancy; Germinoma; RHEUMATOID-ARTHRITIS; OPEN-LABEL; RISK; TUMOR; ETANERCEPT; EFFICACY; CHILDREN; MALIGNANCIES; BLOCKERS; LYMPHOMA;
D O I：
10.1007/s10165-011-0555-z
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We report a 19-year-old patient with systemic-onset juvenile idiopathic arthritis (JIA) who developed a mediastinal germinoma during treatment with infliximab. Although the cancer risk of infliximab is controversial, this agent may have accelerated the growth of the germinoma. We conclude that the indications for tumor necrosis factor (TNF) inhibitors should be strictly decided and that a nationwide cohort study is necessary to assess the risk of cancer in patients with JIA exposed to biologics.
引用
收藏
页码：621 / 624
页数：4
相关论文
共 19 条
[1]   Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists [J].
Askling, J ;
Fored, CM ;
Brandt, L ;
Baecklund, E ;
Bertilsson, L ;
Feltelus, N ;
Cöster, L ;
Geborek, P ;
Jacobsson, LT ;
Lindblad, S ;
Lysholm, J ;
Rantapää-Dahlqvist, S ;
Saxne, T ;
Klareskog, L .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1421-1426
[2]   Disease activity and risk of lymphoma in patients with rheumatoid arthritis:: nested case-control study [J].
Baecklund, E ;
Ekbom, A ;
Sparén, P ;
Feltelius, N ;
Klareskog, L .
BRITISH MEDICAL JOURNAL, 1998, 317 (7152) :180-181
[3]   Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].
Bongartz, T ;
Sutton, AJ ;
Sweeting, MJ ;
Buchan, I ;
Matteson, EL ;
Montori, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285
[4]   Tumor Necrosis Factor α Blockers and Malignancy in Children Forty-Eight Cases Reported to the Food and Drug Administration [J].
Diak, Peter ;
Siegel, Jeffrey ;
La Grenade, Lois ;
Choi, Lauren ;
Lemery, Steven ;
McMahon, Ann .
ARTHRITIS AND RHEUMATISM, 2010, 62 (08) :2517-2524
[5]   Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas [J].
Geborek, P ;
Bladström, A ;
Turesson, C ;
Gulfe, A ;
Petersson, IF ;
Saxne, T ;
Olsson, H ;
Jacobsson, LTH .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (05) :699-703
[6]   Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor α monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis -: Results of an open-label prospective study [J].
Gerloni, V ;
Pontikaki, I ;
Gattinara, M ;
Desiati, F ;
Lupi, E ;
Lurati, A ;
Salmaso, A ;
Fantini, F .
ARTHRITIS AND RHEUMATISM, 2005, 52 (02) :548-553
[7]   Report on malignancies in the German juvenile idiopathic arthritis registry [J].
Horneff, Gerd ;
Foeldvari, Ivan ;
Minden, Kirsten ;
Moebius, Dagmar ;
Hospach, Toni .
RHEUMATOLOGY, 2011, 50 (01) :230-236
[8]   Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis:: an open label study [J].
Lahdenne, P ;
Vähäsalo, P ;
Honkanen, V .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (03) :245-247
[9]  
Lamot L, 2011, CLIN EXP RHEUMATOL, V29, P131
[10]   The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events [J].
Leombruno, J. P. ;
Einarson, T. R. ;
Keystone, E. C. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (07) :1136-1145
12